R&D Systems Inc. Tocris Bioscience Boston Biochem

Moclobemide

Cat. No. 4395

Moclobemide C13H17ClN2O2 [71320-77-9]

Price and Availability

For Moclobemide pricing & availability please select your country from the drop down menu:
Submit
By clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy.

Chemical Name: 4-Chloro-N-[2-(4-morpholinyl)ethyl]­benzamide

Biological Activity

Reversible monoamine oxidase A (MOA-A) inhibitor.

Technical Data

M.Wt:
268.74
Formula:
C13H17ClN2O2
Solubility:
Soluble to 100 mM in DMSO and to 100 mM in ethanol
Purity:
>99 %
Storage:
Store at RT
CAS No:
71320-77-9

The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.

Resources

Certificate of Analysis / Safety Data Sheet

Certificate of Analysis: View current batch
Safety Data Sheet: View Safety Data Sheet

References

Merck Index 12 6309.

Burkard et al (1989) Pharmacological profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. J.Pharmacol.Exp.Ther. 248 391. PMID: 2913284.

Prada et al (1989) Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. J.Pharmacol.Exp.Ther. 248 400. PMID: 2783611.

If you know of a relevant citation for this product please let us know.

View Related Products by Target

5-HT Receptors 5-HT3 Receptors 5-HT-Related Adrenergic Receptors Adrenergic Related Compounds
Dopamine Receptors Dopaminergic-Related Monoamine Oxidase Oxygenases/Oxidases

Keywords: Moclobemide, supplier, reversible, monoamine, oxidase, a, moa-a, inhibitors

Quick Order

Find multiple products by catalog number

divider line

5-HT Review

5-HT Review

Written by Nicholas Barnes and John Neumaier, leading experts. Request a copy or view PDF today.

divider line

7-TM Receptor Signaling

Written by T. Kenakin et al

7-TM Poster

'Seven Transmembrane Receptor Signaling' highlights the multiple behaviors of 7-TMs including G-protein-dependent and -independent signaling as well as the concept of collateral efficacy

divider line

Antidepressants - Current and Future Targets

Written by P. Skolnich et al

Antidepressants poster

'Antidepressants - Current and Future Targets' provides an overview of the current and future targets for the treatment of major depressive disorder.

divider line

New Product Guide

NPG

Highlights over 130 new products added in 2012. Request a copy or view PDF today.

divider line

New Products in this Area

LP 20 hydrochloride

Selective 5-HT7 ligand

Sign-up for new product e-alerts
divider line

20% Discount*

Potent, selective LRRK2 inhibitor

Potent LRRK2 inhibitor now available from Tocris Bioscience

Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.

* Terms & conditions